Pidilizumab, administrated as maintenance therapy after autologous HSCT (auto-HSCT) for diffuse large B cell lymphoma (DLBCL) and nivolumab, administrated as rescue therapy for relapsed HL after auto-HSCT, are well tolerated and ensure a high response rate [100]

Pidilizumab, administrated as maintenance therapy after autologous HSCT (auto-HSCT) for diffuse large B cell lymphoma (DLBCL) and nivolumab, administrated as rescue therapy for relapsed HL after auto-HSCT, are well tolerated and ensure a high response rate [100]. and identify potential strategies to overcome these mechanisms. midostaurin quizartinib gilteritinib crenolanibsorafenibHMA Regulation of cell differentiation and cell growth Up-regulation of HLA and TAA on neoplastic cells, thus improving cellular immune responses against them Reduction of GvHD risk by up-regulation of FoxP3 and subsequent expansion of regulatory T cells azacytidinedecitabineHDACi Down-regulation of genes involved in production of inflammatory cytokines Expansion of regulatory T cells panobinostatICP inhibitors Promotion of T cell responses against tumor cells nivolumabipilimumabpidilizumab Cellular Therapies DLI Direct antitumor activity derived from infused donor T cells DC infusion Stimulation of antitumor cellular response by enhancing DC ability to process and present TAA to host T cells Sipuleucel-TNK cell based therapies Stimulation of antitumor cellular Rabbit Polyclonal to HUCE1 responses by direct infusion of either un-manipulated NK cells or IL-2 pre-treated NK cells Promotion of tumoral lysis by antibody-dependent cellular cytotoxicity by administration of antibodies with a double specificity for TAA expressed on neoplastic cells and CD16 expressed on NK cells Use of anti-KIR antibody to disrupt KIR-HLA interaction and improve NK activation Use of bivalent proteins with a double specificity for both NKG2D activating receptor on NK cells and CD138 on myeloma cells ULBP2-BB4CAR-T cell based therapies Intrinsic antitumoral activity based on ability to recognize specific TAAs and activate T cell cytolytic program against tumor cells Open in a separate window CAR: chimeric antigen receptor, DC: dendritic cells, DLI: donor lymphocyte infusion, HMA: hypomethylating agents, HDACi: inhibitors of histone deacetylase, ICP: immune-checkpoint, NK: natural killer, TAA: tumor associated antigens, TKI: tyrosine kinase inhibitors. 3.1. Tyrosine Kinase Inhibitors (TKI) TKI are drugs with an intrinsic antitumor effect based Decursin on their ability to target tyrosine kinases with aberrant and exaggerated functions selectively expressed by neoplastic clones in a few, specific, hematological malignancies. However, the antitumor effects of TKI also rely on their immunomodulatory effects that allow them to induce Decursin T-cell cytolytic functions, reduce PD-1 expression by T-cells and reduce myeloid-derived suppressor cells [80]. In patients with CML relapsed after allo-HSCT, anti-BCR-ABL TKI (e.g. imatinib) induce more than 60% of molecular remissions [81], whereas results in Ph+ B-ALL relapsed post-transplant are more controversial [82]. However, their use after allo-HSCT is actually recommended by the European Society for Blood and Marrow Transplantation (EBMT) either as prophylaxis or pre-emptive therapy for MRD-negative Ph+ B-ALL patients [83]. In AML the presence of FLT3-ITD at the time of allo-HSCT is predictive of a higher risk of posttransplant relapse (30% vs. 16%) and therapy with anti-FLT3 TKI is of clinical relevance to reduce this risk. Currently, the use of midostaurin, the main FLT3 inhibitor, is approved for AML with mutated FLT3 whereas its use as post-transplant maintenance therapy has been investigated in a phase II clinical trial that reported a 12-month relapse rate of only 9.2% [84]. Sorafenib is another kinase inhibitor that targets a wide range of tyrosine-kinases (e.g., c-KIT, FLT3, VEGFR-2, VEGFR-3, and PDGFR-?) and serine/threonine-kinases (e.g., BRAF, V600E BRAF, and CRAF) expressed by cancer cells including tumor endothelial cells. Results from animal studies have revealed that the antitumor activity of sorafenib not only relies on its ability to inhibit kinases, but also on its ability to induce IL-15 production thereby enhancing T-cell activation and the GvL effect [43]. A retrospective study that investigated sorafenib as a prophylactic therapy in FLT3-ITD positive AML reported an improved outcome [85]. Currently, other newer anti-FLT3 TKI such as quizartinib, gilteritinib, and crenolanib are under investigation. 3.2. Acting on Epigenetic Factors: Hypomethylating Agents and Histone Deacetylase Inhibition Since methylation is a crucial process involved in the epigenetic control of gene expression, it is not surprising that malignant cells use hypermethylation to switch off the expression of a.Thus, a more recent study has questioned whether DLI may be an adequate treatment option in MDS/AML relapsed after HSCT [111] demonstrating that DLI may be effective when combined with chemotherapy or AZA in patients with low leukemic burden, molecular but not hematological relapse, mixed chimerism and favorable cytogenetics and when the time between allo-HSCT and relapse is longer than five months. of immune checkpoint (ICP) inhibitors capable of switching-off the immune response against leukemic cells. Here, we review the main mechanisms of immune escape and identify potential strategies to overcome these mechanisms. midostaurin quizartinib gilteritinib crenolanibsorafenibHMA Regulation of cell differentiation and cell growth Up-regulation of HLA and TAA on neoplastic cells, thus improving cellular immune responses against them Reduction of GvHD risk by up-regulation of FoxP3 and subsequent expansion of regulatory T cells azacytidinedecitabineHDACi Down-regulation of genes involved in production of inflammatory cytokines Expansion of regulatory T cells panobinostatICP inhibitors Promotion of T cell responses against tumor cells nivolumabipilimumabpidilizumab Cellular Therapies DLI Direct antitumor activity derived from infused donor T cells DC infusion Stimulation of antitumor cellular response by enhancing DC ability to process and present TAA to host T cells Sipuleucel-TNK cell based therapies Stimulation of antitumor cellular responses by direct infusion of either un-manipulated NK cells or IL-2 pre-treated NK cells Promotion of tumoral lysis by antibody-dependent cellular cytotoxicity by administration of antibodies with a double specificity for TAA expressed on neoplastic cells and CD16 expressed on NK cells Use of anti-KIR antibody to disrupt KIR-HLA interaction and improve NK activation Use of bivalent proteins with a double specificity for both NKG2D activating receptor on NK cells and CD138 on myeloma cells ULBP2-BB4CAR-T cell based therapies Intrinsic antitumoral activity based on ability to recognize specific TAAs and activate T cell cytolytic program against tumor cells Open in a separate window CAR: chimeric antigen receptor, DC: dendritic cells, DLI: donor lymphocyte infusion, HMA: hypomethylating agents, HDACi: inhibitors of histone deacetylase, ICP: immune-checkpoint, NK: natural killer, TAA: tumor associated antigens, TKI: tyrosine kinase inhibitors. 3.1. Tyrosine Kinase Inhibitors (TKI) TKI are drugs with an intrinsic antitumor effect based on their ability to target tyrosine kinases with aberrant and exaggerated functions selectively expressed by neoplastic clones in a few, specific, hematological malignancies. However, the antitumor effects of TKI also rely on their immunomodulatory effects that allow them to induce T-cell cytolytic functions, reduce PD-1 Decursin expression by T-cells and reduce myeloid-derived suppressor cells [80]. In patients with CML relapsed after allo-HSCT, anti-BCR-ABL TKI (e.g. imatinib) induce more than 60% of molecular remissions [81], whereas Decursin results in Ph+ B-ALL relapsed post-transplant are more controversial [82]. However, their use after allo-HSCT is actually recommended by the European Society for Blood and Marrow Transplantation (EBMT) either as prophylaxis or pre-emptive therapy for MRD-negative Ph+ B-ALL patients [83]. In AML the presence of FLT3-ITD at the time of allo-HSCT is predictive of a higher risk of posttransplant relapse (30% vs. 16%) and therapy with anti-FLT3 TKI is of clinical relevance to reduce this risk. Currently, the use of midostaurin, the main FLT3 inhibitor, is approved for AML with mutated FLT3 whereas its use as post-transplant maintenance therapy has been investigated in a phase II clinical trial that reported a 12-month relapse rate of only 9.2% [84]. Sorafenib is another kinase inhibitor that targets a wide range of tyrosine-kinases (e.g., c-KIT, FLT3, VEGFR-2, VEGFR-3, and PDGFR-?) and serine/threonine-kinases (e.g., BRAF, V600E BRAF, and CRAF) expressed by cancer cells including tumor endothelial cells. Results from animal studies have revealed that the antitumor activity of sorafenib not only relies on its ability to inhibit kinases, but also on its ability to induce IL-15 production thereby enhancing T-cell activation and the GvL effect [43]. A retrospective study that investigated sorafenib as a prophylactic therapy in FLT3-ITD positive AML reported an improved outcome [85]. Currently, other newer anti-FLT3 TKI such as for example quizartinib, gilteritinib, and crenolanib are under analysis. 3.2. Functioning on Epigenetic Elements: Hypomethylating Realtors and Histone Deacetylase Inhibition Since methylation is normally a crucial procedure mixed up in epigenetic control of gene appearance, it isn’t astonishing that malignant cells make use of hypermethylation Decursin to change from the appearance of a number of genes involved with apoptotic cell loss of life and development inhibition. Provided their capability to control cell differentiation and cell development by inhibition of DNA methyltransferase, HMA want AZA and decitabine are accustomed to deal with MDS and AML currently. However, several research have got reported that HMA could also upregulate the appearance of HLA substances and tumor linked antigens (TAAs), improving the power of donor T cells to identify hence, focus on and eliminate tumor cells after allo-HSCT [85,86]. In AML/MDS sufferers with early post-transplant relapse, salvage treatment with decitabine or AZA, administered as one agents or coupled with donor lymphocyte infusion (DLI) can lead to 28% CR [87], an outcome verified by a big EBMT research that reported a minimal incidence of aGvHD also. Oddly enough,.